Long-term efficacy of infliximab in hidradenitis suppurativa

References

• Consensus definition adopted by the second international HS Symposium by the Hidradenitis Suppurativa Foundation, San Francisco 2009. Available from http://www.hs-foundation.org/abouths/what.htm. Accessed August 2011.
   Google Scholar
• Revuz J. Hidradenitis suppurativa. JEADV. 2009;23:985–998.
   Google Scholar
• Wolkenstein P, Loundou A, Barrau K, Auquier P, Revuz J; Quality of Life Group of the French Society of Dermatology. Quality of life impairment in hidradenitis suppurativa: a study of 61 cases. J Am Acad Dermatol. 2007;56:621–623.
   PubMed Web of Science ®Google Scholar
• Pedraz J, Daudén E. Practical management of hidradenitis suppurativa. Actas Dermosifiliogr. 2008;99:101–110.
   Google Scholar
• Grant A, Gonzalez T, Montgomery MO, Cardenas V, Kerdel FA. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. J Am Acad Dermatol. 2010;62:205–217.
   PubMed Web of Science ®Google Scholar
• Adams DR, Yankura JA, Fogelberg AC, Anderson BE. Treatment of hidradenitis suppurativa with etanercept injection. Arch Dermatol. 2010;146:501–504.
   PubMed Web of Science ®Google Scholar
• Miller I, Lynggaard CD, Lophaven S, Zachariae C, Dufour DN, Jemec GB. A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa. Br J Dermatol. 2011;165:391–398.
   PubMed Web of Science ®Google Scholar
• Remicade, INN-Infliximab-EMA. Available from http://www.ema.europa.eu/docs/en_GB/document_library/EPAR__Product_Information/human/000240/WC500050888.pdf.Accessed August 2011.
   Google Scholar
• Hurley HJ. Axillary hiperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa, and familial benign pemphigus: Surgical approach. In Roenigk RK, Roenigk HHJ, editors. Dermatologic surgery, principles and practice. New York, NY: Marcel Dekker, 1989. p. 729–739.
   Google Scholar
• Sartorius K, Lapins J, Emtestam L, Jemec GB. Suggestions for uniform outcome variables when reporting treatment effects in hidradenitis suppurativa. Br J Dermatol. 2003;149:211–213.
   PubMed Web of Science ®Google Scholar
• Lebwohl B, Sapadin AN. Infliximab for the treatment of hidradenitis suppurativa. J Am Acad Dermatol. 2003;49(5 Suppl):S275–S276.
   Google Scholar
• Sullivan TP, Welsh E, Kerdel FA, Burdick AE, Kirsner RS. Infliximab for hidradenitis suppurativa. Br J Dermatol. 2003;149:1046–1049.
   PubMed Web of Science ®Google Scholar
• Adams DR, Gordon KB, Devenyi AG, Ioffreda MD. Severe hidradenitis suppurativa treated with infliximab infusion. Arch Dermatol. 2003;139:1540–1542.
   PubMed Web of Science ®Google Scholar
• Thielen AM, Barde C, Saurat JH. Long-term infliximab for severe hidradenitis suppurativa. Br J Dermatol. 2006;155:1105–1107.
   PubMed Web of Science ®Google Scholar
• Usmani N, Clayton TH, Everett S, Goodfield MD. Variable response of hidradenitis suppurativa to infliximab in four patients. Clin Exp Dermatol. 2007;32:204–205.
   PubMed Web of Science ®Google Scholar
• Pedraz J, Daudén E, Pérez-Gala S, Goiriz-Valdés R, Fernández-Peñas P, García-Diez A. Hidradenitis suppurativa. Response to treatment with infliximab. Actas Dermosifiliogr. 2007;98:325–331.
   PubMedGoogle Scholar
• Mekkes JR, Bos JD. Long-term efficacy of a single course of infliximab in hidradenitis suppurativa. Br J Dermatol. 2008;158:370–374.
   PubMed Web of Science ®Google Scholar
• Goertz RS, Konturek PC, Naegel A, Janka R, Amann K, Maennlein G, Experiences with a long-term treatment of a massive gluteal acne inversa with infliximab in Crohn's disease. Med Sci Monit. 2009;15:CS14–CS18.
   PubMedGoogle Scholar
• Torres T, Selores M. Treatment of hidradenitis suppurativa with infliximab. An Bras Dermatol. 2010;85:576.
   PubMedGoogle Scholar
• Lasocki A, Sinclair R, Foley P, Saunders H. Hidradenitis suppurativa responding to treatment with infliximab. Australas J Dermatol. 2010;51:186–190.
   PubMed Web of Science ®Google Scholar
• Deschamps ME, Payet S, Tournadre A, Soubrier M, Souteyrand P, D'Incan M. Efficacy of infliximab in the treatment of follicular occlusion triad. Ann Dermatol Venereol. 2010;137:546–550.
   PubMedGoogle Scholar
• Alecsandru D, Padilla B, Izquierdo JA, Fernández-Cruz E, Sánchez-Ramón S. Severe refractory hidradenitis suppurativa in an HIV-positive patient successfully treated with infliximab. Arch Dermatol. 2010;146:1343–1345.
   PubMed Web of Science ®Google Scholar
• Roussomoustakaki M, Dimoulios P, Chatzicostas C, Kritikos HD, Romanos J, Panayiotides JG, Hidradenitis suppurativa associated with Crohn's disease and spondyloarthropathy: response to anti-TNF therapy. J Gastroenterol. 2003;38:1000–1004.
   PubMed Web of Science ®Google Scholar
• Fardet L, Dupuy A, Kerob D, Levy A, Allez M, Begon E, Infliximab for severe hidradenitis suppurativa: transient clinical efficacy in 7 consecutive patients. J Am Acad Dermatol. 2007;56:624–628.
   PubMed Web of Science ®Google Scholar
• Fernández-Vozmediano JM, Armario-Hita JC. Infliximab for the treatment of hidradenitis suppurativa. Dermatology. 2007;215:41–44.
   PubMedGoogle Scholar
• Moschella SL. Is there a role for infliximab in the current therapy of hidradenitis suppurativa? A report of three treated cases. Int J Dermatol. 2007;46:1287–1291.
   PubMed Web of Science ®Google Scholar
• Brunasso AM, Delfino C, Massone C. Hidradenitis suppurativa: are tumour necrosis factor-alpha blockers the ultimate alternative? Br J Dermatol. 2008;159:761–763.
   PubMedGoogle Scholar
• Haslund P, Lee RA, Jemec GB. Treatment of hidradenitis suppurativa with tumour necrosis factor-alpha inhibitors. Acta Derm Venereol. 2009;89:595–600.
   PubMed Web of Science ®Google Scholar
• Brunasso AM, Massone C. Treatment of hidradenitis suppurativa with tumour necrosis factor-alpha inhibitors: an update on infliximab. Acta Derm Venereol. 2011;91:70–71.
   PubMed Web of Science ®Google Scholar
• Clemmensen OJ. Topical treatment of hidradenitis suppurativa with clindamycin. Int J Dermatol. 1983;22:325–328.
   PubMed Web of Science ®Google Scholar
• Jemec GB, Wendelboe P. Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa. J Am Acad Dermatol. 1998;39:971–974.
   PubMed Web of Science ®Google Scholar
• Mortimer PS, Dawber RP, Gales MA, Moore RA. A double-blind controlled cross-over trial of cyproterone acetate in females with hidradenitis suppurativa. Br J Dermatol. 1986;115:263–268.
   PubMed Web of Science ®Google Scholar
• Paradela S, Fonseca E. Treatment of hidradenitis suppurativa. Treat Strateg Dermatol. 2011;1:92–95.
   Google Scholar
• Kraft JN, Searles GE. Hidradenitis suppurativa in 64 female patients: retrospective study comparing oral antibiotics and antiandrogen therapy. J Cutan Med Surg. 2007;11:125–131.
   PubMed Web of Science ®Google Scholar
• Boer J, van Gemert MJ. Long-term results of isotretinoin in the treatment of 68 patients with hidradenitis suppurativa. J Am Acad Dermatol. 1999;40:73–76.
   PubMed Web of Science ®Google Scholar
• Kaur MR, Lewis HM. Hidradenitis suppurativa treated with dapsone: a case series of five patients. J Dermatolog Treat. 2006;17:211–213.
   PubMed Web of Science ®Google Scholar
• Ritz JP, Runkel N, Haier J, Buhr HJ. Extent of surgery and recurrence rate of hidradenitis suppurativa. Int J Colorectal Dis. 1998;13:164–168.
   PubMed Web of Science ®Google Scholar
• Watson JD. Hidradenitis suppurativa – a clinical review. Br J Plast Surg. 1985;38:567–569.
   PubMedGoogle Scholar
• Harrison BJ, Mudge M, Hughes LE. Recurrence after surgical treatment of hidradenitis suppurativa. Br Med J (Clin Res Ed). 1987;294:487–489.
   PubMed Web of Science ®Google Scholar
• Mandal A, Watson J. Experience with different treatment modules in hidradenitis suppurativa: a study of 106 cases. Surgeon. 2005;3:23–26.
   Google Scholar
• van der Zee HH, de Ruiter L, van den Broecke DG, Dik WA, Laman JD, Prens EP. Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-1β. Br J Dermatol. 2011;164:1292–1298.
   PubMed Web of Science ®Google Scholar
• Matusiak L, Bieniek A, Szepietowski JC. Increased serum tumour necrosis factor-alpha in hidradenitis suppurativa patients: is there a basis for treatment with anti-tumour necrosis factor-alpha agents? Acta Derm Venereol. 2009;89:601–603.
   PubMed Web of Science ®Google Scholar
• Fimmel S, Zouboulis CC. Comorbidities of hidradenitis suppurativa (acne inversa). Dermatoendocrinol. 2010;2:9–16.
   PubMedGoogle Scholar
• Vander Cruyssen B, Durez P, Westhovens R, De Keyser F. Seven-year follow-up of infliximab therapy in rheumatoid arthritis patients with severe long-standing refractory disease: attrition rate and evolution of disease activity. Arthritis Res Ther. 2010;12:R77.
   PubMed Web of Science ®Google Scholar
• Brunasso AM, Massone C. Rotational therapy with TNF-alpha blockers for recalcitrant hidradenitis suppurativa. Eur J Dermatol. 2010;20:644–646.
   Google Scholar
• van Rappard DC, Mekkes JR. Treatment of severe hidradenitis suppurativa with infliximab in combination with surgical interventions. Br J Dermatol. In press.
   Google Scholar